SILDENAFIL AND CHRONIC PROSTATITIS

Cover Page


Cite item

Full Text

Abstract

Prostate stands in close anatomical and functional relations with urethra, genital glands and other pelvic organs. Inflammatory process in prostate is almost universally associated with inflammation in other genitourinary organs as well as sexual dysfunction, abnormal spermogram, psycho-emotional disorders and, in elderly men, with benign prostatic hyperplasia. Sildenafil (phosphodiesterase-5 inhibitor) is effective in the treatment of erectile dysfunction, testicular insufficiency and depression which may persist after the standard therapy of chronic prostatitis and is recommended as add-on to rehabilitation procedures after chronic prostatitis therapy.

About the authors

V. A. Molochkov

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Author for correspondence.
Email: derma@monikiweb.ru
MD, PhD, Professor, Head of the Dermatovenereology and Dermato-Oncology Department Россия

References

  1. Каплун МИ. Хронический неспецифический простатит. Уфа: Башкирское книжное издательство; 1984. 128 с. (Кaplun MI. Chronic nonspecific prostatitis. Ufa: Bashkirskoe knizhnoe izdatel’stvo; 1984. 128 р. Russian).
  2. Молочков ВА, Ильин ИИ. Хронический уретрогенный простатит. М.: Медицина; 2004. 288 с. (Molochkov VA, Il’in II. Chronic urethrogenic prostatitis. Moscow: Meditsina; 2004. 288 р. Russian).
  3. May F. Zur Differential diagnose der chronischen prostatitis. Med Klinik. 1962;57:676–9.
  4. Юнда ИФ. Простатиты. Киев: Здоров’я; 1974. 192 с.
  5. (Yunda IF. Prostatitis. Kiev: Zdorov’ya; 1974. 192 р. Russian).
  6. Камалов АА, Дорофеев СД, Eфремов ЕА. Современная медикаментозная терапия эректильной дисфункции. Consilium Medicum. 2006;8(4):57–62.
  7. (Kamalov AA, Dorofeev SD, Efremov EA. [Modern drug treatment for erectile dysfunction]. Consilium Мedicum. 2006;8(4):57–62. Russian).
  8. Capitanio U, Salonia A, Briganti A, Montorsi F. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int J Clin Pract. 2013;67(6):544–51.
  9. Kirby RS, Carson C 3rd, Dasgupta P. Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/ prostatodynia? BJU Int. 2014;113(5):694–5.
  10. Doggrell SA. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin Pharmacother. 2005;6(1):75–84.
  11. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol. 2008;26(6):603–9.
  12. Caremel R, Oger-Roussel S, Behr-Roussel D, Grise P, Giuliano F. Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article. Prog Urol. 2010;20(9):616–26.
  13. Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 2011;72(2):197–204.
  14. Барабанов ЛГ. Функциональное состояние гипофиза, половых желез и коры надпочечников при лечении больных гонореей, осложненной простатитом. Вестник дерматологии. 1989;(7):69–74.
  15. (Barabanov LG. [Functional status of hypophysis, genital glands and adrenal cortex and its role in patients with gonorrhea and associated prostatitis]. Vestnik dermatologii. 1989;(7):69–74. Russian).
  16. Lefièvre L, De Lamirande E, Gagnon C. The cyclic GMP-specific phosphodiesterase inhibitor, sildenafil, stimulates human sperm motility and capacitation but not acrosome reaction. J Androl. 2000;21(6):929–37.
  17. Боржиевский ЦК, Фельдман МЮ. Лечение больных хроническим простатитом на курорте Моршин. Вестник дерматологии. 1986;(1):64–7.
  18. (Borzhievskiy TsK, Fel’dman MYu. [Treatment of patients with chronic prostatitis at the Morshin resort]. Vestnik dermatologii. 1986;(1):64–7. Russian).
  19. Федоренко АE, Коляденко ВГ. Динамика психологической и соматической составляющей тревожности при поражениях мочеполовых органов у мужчин. Вестник дерматологии. 1991;(10):47–9.
  20. (Fedorenko AE, Kolyadenko VG. [Dynamics of psychological and somatic components of anxiety in patients with genitourinary disorders]. Vestnik dermatologii. 1991;(10):47–9. Russian).
  21. Egan KJ, Krieger JN. Psychological problems in chronic prostatitis patients with pain. Clin J Pain. 1994;10(3):218–26.
  22. Моргунов ЛЮ. Силденафил: только ли лечение эректильной дисфункции? Эффективная фармакотерапия. 2013;(1):46–9. (Morgunov LYu. [Sildenafil: therapy of erectile dysfunction or more?]. Effektivnaya farmakoterapiya. 2013;(9):46–9. Russian).
  23. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338(20):1397– 404.
  24. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol. 1999;162(3 Pt 1):722–5.
  25. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res. 1998;10(2):69–73.
  26. Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra). Urology. 2002;60(2 Suppl 2):67–90.
  27. McMahon CG. High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res. 2002;14(6):533–8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Molochkov V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies